return to corporate website
Menu
Return to
www.noxopharm.com
Home
About Us
About Noxopharm
Board of Directors
Management Team
Corporate Governance
Company Constitution
Sustainability
Noxopharm History
Research and Clinical Programs
Research and Clinical Programs
About Pharmorage
Investor Centre
Share Price
ASX Announcements
Why Invest in Noxopharm
Presentations & Interviews
Annual Reports
Financial Reports
Analyst Reports
Investor Fact Sheet
Investor FAQs
Upcoming Events
Privacy Policy
Share Registry Information
Media Centre
Overview
Newsletters
Coverage
Investor Videos
NOX Insights
Noxopharm Podcasts
Contact Us
Contact Us
Partnering
Working at Noxopharm
Newsletter Email Alerts
ASX Announcements Email Alerts
Investor Centre
Home
>
Investor Centre
>
ASX Announcements
Share Price
ASX Announcements
Why Invest in Noxopharm
Presentations & Interviews
Annual Reports
Financial Reports
Analyst Reports
Investor Fact Sheet
Investor FAQs
Upcoming Events
Privacy Policy
Share Registry Information
ASX Announcements
Filter by Year:
2022
2021
2020
2019
2018
2017
2016
21-Dec-2018
Change of Director's Interest Notice - GK
21-Dec-2018
Section 708 Certificate
21-Dec-2018
Appendix 3B
20-Dec-2018
NOX Receives $3.26M Federal Govt R&D Rebate
11-Dec-2018
DARRT-1 study advancing on basis of positive clinical data
29-Nov-2018
NOX announces Positive Data from CEP-1 Study of Veyonda
21-Nov-2018
Initial Director's Interest Notice
21-Nov-2018
Results of Meeting
21-Nov-2018
Appointment of Mr John Moore as Non-Executive Director
21-Nov-2018
NOX 2018 AGM Presentations
1
2
3
4
5
6
7
8
Next
